PMID- 38220554
OWN - NLM
STAT- MEDLINE
DCOM- 20240315
LR  - 20240325
IS  - 1878-108X (Electronic)
IS  - 0166-2236 (Linking)
VI  - 47
IP  - 3
DP  - 2024 Mar
TI  - An integrative view on the cell-type-specific mechanisms of ketamine's 
      antidepressant actions.
PG  - 195-208
LID - S0166-2236(23)00291-6 [pii]
LID - 10.1016/j.tins.2023.12.004 [doi]
AB  - Over the past six decades, the use of ketamine has evolved from an anesthetic and 
      recreational drug to the first non-monoaminergic antidepressant approved for 
      treatment-resistant major depressive disorder (MDD). Subanesthetic doses of 
      ketamine and its enantiomer (S)-ketamine (esketamine) directly bind to several 
      neurotransmitter receptors [including N-methyl-d-aspartic acid receptor (NMDAR), 
      kappa and mu opioid receptor (KOR and MOR)] widely distributed in the brain and across 
      different cell types, implicating several potential molecular mechanisms 
      underlying the action of ketamine as an antidepressant. This review examines 
      preclinical studies investigating cell-type-specific mechanisms underlying the 
      effects of ketamine on behavior and synapses. Cell-type-specific approaches are 
      crucial for disentangling the critical mechanisms involved in the therapeutic 
      effect of ketamine.
CI  - Copyright (c) 2023 Elsevier Ltd. All rights reserved.
FAU - Lewis, Vern
AU  - Lewis V
AD  - Department of Neuroscience, Carleton University, Health Sciences Building, 1125 
      Colonel By Drive, Ottawa, Ontario K1S 5B6, Canada.
FAU - Rurak, Gareth
AU  - Rurak G
AD  - Department of Neuroscience, Carleton University, Health Sciences Building, 1125 
      Colonel By Drive, Ottawa, Ontario K1S 5B6, Canada.
FAU - Salmaso, Natalina
AU  - Salmaso N
AD  - Department of Neuroscience, Carleton University, Health Sciences Building, 1125 
      Colonel By Drive, Ottawa, Ontario K1S 5B6, Canada.
FAU - Aguilar-Valles, Argel
AU  - Aguilar-Valles A
AD  - Department of Neuroscience, Carleton University, Health Sciences Building, 1125 
      Colonel By Drive, Ottawa, Ontario K1S 5B6, Canada. Electronic address: 
      argel.aguilavalles@carleton.ca.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20240113
PL  - England
TA  - Trends Neurosci
JT  - Trends in neurosciences
JID - 7808616
RN  - 690G0D6V8H (Ketamine)
RN  - 0 (Antidepressive Agents)
RN  - 0 (Receptors, N-Methyl-D-Aspartate)
SB  - IM
MH  - Humans
MH  - *Ketamine/pharmacology/therapeutic use
MH  - *Depressive Disorder, Major/drug therapy
MH  - Antidepressive Agents/pharmacology/therapeutic use
MH  - Depression/drug therapy
MH  - Brain/metabolism
MH  - Receptors, N-Methyl-D-Aspartate
OTO - NOTNLM
OT  - circuits
OT  - glia
OT  - interneurons
OT  - plasticity
OT  - psychiatric disease
OT  - rapidly acting antidepressant
COIS- Declaration of interests A.A.-V. serves as a scientific advisor to BetterLife 
      Pharma. The other authors have no competing interests in relation to this work.
EDAT- 2024/01/15 00:42
MHDA- 2024/03/15 06:44
CRDT- 2024/01/14 22:04
PHST- 2023/06/21 00:00 [received]
PHST- 2023/11/08 00:00 [revised]
PHST- 2023/12/22 00:00 [accepted]
PHST- 2024/03/15 06:44 [medline]
PHST- 2024/01/15 00:42 [pubmed]
PHST- 2024/01/14 22:04 [entrez]
AID - S0166-2236(23)00291-6 [pii]
AID - 10.1016/j.tins.2023.12.004 [doi]
PST - ppublish
SO  - Trends Neurosci. 2024 Mar;47(3):195-208. doi: 10.1016/j.tins.2023.12.004. Epub 
      2024 Jan 13.